Published On : September 2026
A buyer or provider assuming large pharmaceutical companies are the only meaningful end user in this market is skipping a distinction that actually shapes how discovery partnership demand is structured: end user diversity.
Within the cellular DNA-encoded library screening market, end user diversity across large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations, not large pharma alone, is what defines this screening market's buyer base.
This page describes seven therapeutic application categories and six end user categories strictly as market segments.
It provides no diagnostic, treatment-planning or patient-outcome guidance, and makes no claim about clinical efficacy, treatment outcome or comparative therapeutic performance for any application or company.
A venture-backed biotech firm pursuing a single therapeutic application generally has different provider requirements than an academic consortium exploring multiple target classes across several applications at once.
That is why business development teams experienced in this market map end user type alongside therapeutic application rather than assuming a one-size-fits-all buyer profile.
Six end user categories complete the specification once therapeutic application is settled, spanning large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations.
For buyers, recognizing where a program's own end user type sits relative to these six categories helps clarify what scale of engagement a DEL screening provider is likely to expect.
For providers, therapeutic application and end user breadth together widen the addressable share of any given discovery partner's program requirements, particularly among partners whose focus spans more than one application area.
End user type also shapes sales cycle length, since an academic consortium's exploratory evaluation phase generally runs on a different timeline than a large pharmaceutical company's more structured contract negotiation process.
Government research organizations and translational medicine centers, though smaller by volume than large pharma or emerging biotech, often bring specific public-health or institutional priorities that shape which therapeutic applications they pursue through DEL screening.
Oncology and immunology and inflammation form two of the seven therapeutic application categories tracked in this report, both named here strictly as market categories with no claim made about the clinical outcome of any oncology or immunology program.
Oncology is the largest therapeutic application category tracked in this report by discovery partnership volume, reflecting the breadth of target classes, including kinases, protein-protein interactions and E3 ligases, that oncology programs draw on.
Immunology and inflammation is the fastest-growing therapeutic application category tracked in this report, as difficult-to-drug immune-pathway targets draw increased discovery partnership investment from both large pharma and emerging biotech buyers.
The providers most active across these therapeutic applications are covered in this report's supplier landscape by provider type, which separates specialist DEL platform providers from in-house pharma platforms and CRO or discovery-service providers active across oncology and immunology programs alike.
Providers with demonstrated experience across both oncology and immunology and inflammation programs are generally better positioned to support a discovery partner whose therapeutic focus broadens over the life of a multi-year partnership.
Buyers new to immunology and inflammation programs frequently start with a smaller pilot engagement before expanding, reflecting the comparatively newer status of this therapeutic application relative to the more established oncology category.
|
BUYER INSIGHT Buyers pursuing immunology and inflammation targets increasingly request a provider's specific protein-protein interaction and transcription factor experience, since these two target classes feature disproportionately in this therapeutic application relative to more conventional oncology target classes such as kinases. |
Neuroscience, infectious diseases and metabolic disorders form three further therapeutic application categories tracked in this report, each representing a smaller but distinct share of discovery partnership activity relative to oncology.
Neuroscience programs generally draw on ion channel and GPCR target classes more heavily than the average therapeutic application tracked in this report, reflecting the prominence of these target classes in neurological drug discovery.
Infectious disease programs generally have shorter, more urgency-driven scientific assessment cycles than the average DEL screening program, reflecting the time-sensitive nature of infectious disease drug discovery relative to some chronic disease areas.
Metabolic disorder programs frequently overlap with cardiovascular disease programs in target class focus, given the biological connections between metabolic and cardiovascular pathways that several discovery teams pursue together.
Government research organizations are disproportionately active in infectious disease programs relative to the other therapeutic applications tracked in this report, reflecting public health considerations that shape funding for this application category.
Rare disease and cardiovascular disease applications complete the therapeutic application dimension tracked in this report.
Rare disease programs are frequently pursued by academic consortia and translational medicine centers alongside emerging biotech companies, reflecting the smaller patient populations and correspondingly different commercial calculus that rare disease drug discovery generally involves.
Cardiovascular disease programs draw on a broad mix of target classes tracked in this report, including GPCRs, ion channels and kinases, reflecting the range of biological pathways implicated in cardiovascular disease.
Emerging therapeutic opportunities identified in this report's competitive mapping include several rare disease programs where DEL screening's ability to address difficult-to-drug targets is particularly valuable given how few alternative discovery approaches exist for some rare disease targets.
Translational medicine centers frequently bridge rare disease discovery work with the broader preclinical development process, given how closely rare disease programs depend on specialized institutional expertise relative to more common disease areas.
Buyer scale classification also correlates with therapeutic application choice, since early-stage venture-funded firms are more frequently associated with rare disease programs than with the broader cardiovascular disease category, which draws more consistently from mid-market and top-tier pharma buyers alike.
Large pharmaceutical companies and emerging biotech companies form two of the six end user categories tracked in this report, representing the two largest buyer segments by discovery partnership volume.
Large pharmaceutical companies generally operate the largest and most diversified discovery partnership portfolios among the end user categories tracked in this report, often engaging multiple DEL screening providers across different target classes simultaneously.
Emerging biotech companies, including venture-backed biotech firms and specialty discovery companies, generally operate a narrower, more focused discovery partnership portfolio than large pharma, often concentrated on a single therapeutic application or target class.
Both end user categories access DEL screening across the same five engagement models tracked in this report, though large pharmaceutical companies more frequently pursue platform access models while emerging biotech companies more frequently start with fee-for-service screening before expanding.
The pace at which an emerging biotech company scales its DEL screening engagement often tracks its own funding cycle, expanding from a single fee-for-service round toward a broader discovery partnership program as additional funding becomes available.
Contract research organizations, academic research institutes, translational medicine centers and government research organizations complete the end user dimension tracked in this report.
Contract research organizations generally act as an intermediary end user, accessing DEL screening on behalf of a pharmaceutical or biotech client rather than for a wholly internal discovery program.
Academic research institutes and academic consortia generally pursue DEL screening through smaller, more exploratory engagements than industry end users, often concentrated on target identification and hit discovery rather than later discovery stages.
Translational medicine centers and government research organizations round out this report's end user categories, each representing a smaller but genuinely distinct buyer profile relative to the four other end user categories tracked here.
The engagement models each end user typically uses differ meaningfully across these four categories, detail covered in this report's engagement model and purchasing pathway breakdown, which explains why a CRO's procurement pattern generally looks different from an academic consortium's.
Buyers selecting between these four end user pathways as a discovery model, for example a biotech firm considering whether to route work through a CRO rather than a direct specialist provider relationship, generally weigh internal scientific capacity against the convenience of a bundled service relationship.
Sales cycle length also differs meaningfully across these four end user types, with government research organizations and academic institutes generally following longer, more procedurally structured procurement cycles than a venture-backed biotech firm moving quickly to secure a competitive advantage.
This report tracks seven therapeutic application categories: oncology, immunology and inflammation, neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases, with oncology the largest and immunology and inflammation the fastest-growing.
End users include large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations.
Yes. Academic research institutes and academic consortia are one of six end user categories tracked in this report, generally pursuing smaller, more exploratory DEL screening engagements concentrated on target identification and hit discovery.
End user diversity across large pharma, emerging biotech, CROs, academic institutes, translational centers and government organizations, not large pharma alone, is what defines this screening market's buyer base and shapes how discovery partnership demand is structured.
No. Oncology is the largest therapeutic application category tracked in this report by discovery partnership volume, but immunology and inflammation is growing faster, and neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases each represent distinct additional application categories.